SCHEMBL25909825

SCHEMBL25909825

CC(C)(C)OC(=O)n1c(B2OC(C)(C)C(C)(C)O2)cc2ncc(Br)cc21

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.36
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA1 P14867 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRA6 Q16445 1/20 0.33
DGAT1 O75907 1/20 0.31
AURKA O14965 1/20 0.31
CDK2 P24941 1/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31
CCNB2 O95067 1/20 0.31
CDK1 P06493 1/20 0.31
CCNB1 P14635 1/20 0.31
GSK3B P49841 1/20 0.31
CCNB3 Q8WWL7 1/20 0.31
AAK1 Q2M2I8 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30466269 1.00 USP30 (0.36) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL25229654 0.86 USP30 (0.36) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL25909834 0.86 USP30 (0.30) USP30GABRG2GABRB3GABRA5
SCHEMBL29814617 0.81 USP30 (0.37) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL3424231 0.80 USP30 (0.39) USP30CCNB2CDK1CCNB1GSK3B
SCHEMBL25909829 0.78 USP30 (0.38) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL29377339 0.78 GABRG2 (0.38) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL16729363 0.78 GABRG2 (0.38) USP30GABRG2GABRB3GABRA5GABRA1
SCHEMBL616604 0.74 NR1H2 (0.48)
SCHEMBL30466370 0.74 NR1H2 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists SAIL BIOMEDICINES, INC. 2023-07-27 US disclosed
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists SAIL BIOMEDICINES, INC. 2023-07-27 US disclosed
WO-2023114428-A1 HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE Vir Biotechnology, Inc. (US) 2023-06-22 WO disclosed
WO-2021242955-A1 FUSED AZOLE HETEROCYCLES AS AHR ANTAGONISTS SENDA BIOSCIENCES, INC. (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists AHR, ARNT, AIPL1 USP30 1929/4885GABRG2 1322/4885GABRB3 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.